Faropenem

Faropenem
Faropenem
Clinical data
AHFS/Drugs.com International Drug Names
Pregnancy cat.  ?
Legal status  ?
Routes Oral
Identifiers
CAS number 106560-14-9 N
ATC code None
PubChem CID 65894
ChemSpider 59303 YesY
UNII F52Y83BGH3 YesY
ChEBI CHEBI:51257 YesY
ChEMBL CHEMBL556262 YesY
Chemical data
Formula C12H15NO5S 
Mol. mass 285.317 g/mol
SMILES eMolecules & PubChem
 N(what is this?)  (verify)

Faropenem is an orally-active beta-lactam antibiotic belonging to the penem group.[1]

It is resistant to some forms of extended-spectrum beta-lactamase.[2]

It is orally available.[3]

Contents

Forms

Faropenem was developed by Daiichi Asubio Pharma, which markets it in two forms.

  • The sodium salt faropenem sodium, available under the trade name Farom, has been marketed in Japan since 1997. (PubChem 636379)
  • The prodrug form faropenem medoxomil[4] (also known as faropenem daloxate) has been licensed from Daiichi Asubio Pharma by Replidyne, which plans to market it in conjunction with Forest Pharmaceuticals. The trade name proposed for the product was Orapem but company officials recently announced that this name was rejected by the FDA. (Q1 06 Investor Conf Call)(PubChem 6918218)

The company also stated their hope to have the product available for commercial sale months before the 2007 influenza season.[citation needed]

Clinical use

Faropenem has yet to receive marketing approval in the United States, and was submitted for consideration by the United States Food and Drug Administration (FDA) on 20 December 2005. The new drug application (NDA) dossier submitted included four proposed indications:

  • acute bacterial sinusitis
  • community acquired pneumonia
  • acute exacerbations of chronic bronchitis
  • uncomplicated skin and skin structure infections

History

FDA rejects Replidyne’s faropenem Louisville firm drug rejected; considered “nonapprovable’ 10/24/06 The US Food and Drug Administration (FDA) refused to approve faropenem, an antibiotic manufactured by Louisville-based Replidyne. The FDA said the drug was “nonapprovable,” but did not refer to specific safety concerns about the product.

The company will have to conduct new studies and clinical trials, lasting an estimated two more years, to prove the drug treats community-acquired pneumonia, bacterial sinusitis, chronic bronchitis and skin infections.

References

External links


Wikimedia Foundation. 2010.

Игры ⚽ Поможем сделать НИР

Look at other dictionaries:

  • Ampicillin — Systematic (IUPAC) name (2S,5R,6R) 6 ([(2R) 2 amino 2 phenylace …   Wikipedia

  • Amoxicillin — Systematic (IUPAC) name (2S,5R,6R) 6 …   Wikipedia

  • Penicillin — For the Japanese band, see Penicillin (band). Penicillin core structure. The R is the variable group. Penicillin (sometimes abbreviated PCN or pen) is a group of antibiotics derived from Penicillium fungi.[1] They include …   Wikipedia

  • Beta-lactam antibiotic — β lactam antibiotics are a broad class of antibiotics that include penicillin derivatives, cephalosporins, monobactams, carbapenems, and β lactamase inhibitors, that is, any antibiotic agent that contains a β lactam nucleus in its molecular… …   Wikipedia

  • Meticillin — Systematic (IUPAC) name (2S,5R,6R) 6 [(2,6 dimethoxybenzoyl)amino] 3,3 dimethyl 7 oxo 4 thia 1 azabicyclo[3.2.0]heptane 2 carboxylic acid Clinical data …   Wikipedia

  • Lysozyme — single crystal Identifiers EC number 3.2.1.17 …   Wikipedia

  • Isoniazid — Systematic (IUPAC) name isonicotinohydrazide …   Wikipedia

  • Cephalosporin — See also: Discovery and development of cephalosporins Core structure of the cephalosporins …   Wikipedia

  • Aztreonam — Systematic (IUPAC) name 2 ({[(1Z …   Wikipedia

  • Cephamycin — Cefoxitin Cefotetan …   Wikipedia

Share the article and excerpts

Direct link
Do a right-click on the link above
and select “Copy Link”